 Akers Biosciences Inc NASDAQ: AKER and its proposed merger partner MyMD Pharmaceuticals Inc have announced new data for MYMD-1 from the Eurofins Discovery Phenotypic Center of Excellence study. MYMD-1 is being evaluated for autoimmune and age-related diseases. 